JP2022505925A5 - - Google Patents
Info
- Publication number
- JP2022505925A5 JP2022505925A5 JP2021523011A JP2021523011A JP2022505925A5 JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5 JP 2021523011 A JP2021523011 A JP 2021523011A JP 2021523011 A JP2021523011 A JP 2021523011A JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754383P | 2018-11-01 | 2018-11-01 | |
| US62/754,383 | 2018-11-01 | ||
| PCT/US2019/059555 WO2020093023A1 (en) | 2018-11-01 | 2019-11-01 | Anti-tim-3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505925A JP2022505925A (ja) | 2022-01-14 |
| JP2022505925A5 true JP2022505925A5 (https=) | 2022-11-08 |
Family
ID=69159931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523011A Pending JP2022505925A (ja) | 2018-11-01 | 2019-11-01 | 抗ｔｉｍ－３抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220081480A1 (https=) |
| EP (1) | EP3873611A1 (https=) |
| JP (1) | JP2022505925A (https=) |
| CN (1) | CN113272017A (https=) |
| AU (1) | AU2019371457A1 (https=) |
| CA (1) | CA3117429A1 (https=) |
| IL (1) | IL282707A (https=) |
| WO (1) | WO2020093023A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7214440B2 (ja) * | 2018-11-01 | 2023-01-30 | 三菱重工エンジニアリング株式会社 | 検証処理装置、検証処理方法及びプログラム |
| EP4372006A4 (en) * | 2021-07-16 | 2025-10-08 | Brightpath Biotherapeutics Co Ltd | ANTIBODY OR ANTIBODY DERIVATIVE TO TIM-3 ANTIGEN, AND USE THEREOF |
| WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| AU2023300419A1 (en) | 2022-07-01 | 2025-01-02 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| WO2025202222A1 (en) | 2024-03-25 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells |
| WO2026059950A1 (en) * | 2024-09-10 | 2026-03-19 | Agilent Technologies, Inc. | Anti-human tim3 antibodies for in vitro diagnostics |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| KR20170075778A (ko) * | 2014-10-27 | 2017-07-03 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 항-tim-3 항체 |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| EP3878465A1 (en) * | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| PE20181326A1 (es) * | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| CN109757103B (zh) * | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| MX2019005116A (es) * | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
| WO2018129553A1 (en) * | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| MY202480A (en) | 2017-05-12 | 2024-04-30 | Shanghai hengrui pharmaceutical co ltd | Fusion protein containing tgf- receptor and medicinal uses thereof |
-
2019
- 2019-11-01 WO PCT/US2019/059555 patent/WO2020093023A1/en not_active Ceased
- 2019-11-01 CN CN201980086657.5A patent/CN113272017A/zh active Pending
- 2019-11-01 EP EP19835889.7A patent/EP3873611A1/en not_active Withdrawn
- 2019-11-01 CA CA3117429A patent/CA3117429A1/en active Pending
- 2019-11-01 JP JP2021523011A patent/JP2022505925A/ja active Pending
- 2019-11-01 AU AU2019371457A patent/AU2019371457A1/en not_active Abandoned
-
2021
- 2021-04-27 IL IL282707A patent/IL282707A/en unknown
- 2021-04-30 US US17/245,474 patent/US20220081480A1/en not_active Abandoned